Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Overexpression of Cyclin L2 Inhibits Growth and Enhances Chemosensitivity in Human Gastric Cancer Cells

  • Li, Hong-Li (Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital) ;
  • Huang, Ding-Zhi (Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital) ;
  • Deng, Ting (Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital) ;
  • Zhou, Li-Kun (Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital) ;
  • Wang, Xia (Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital) ;
  • Bai, Ming (Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital) ;
  • Ba, Yi (Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cyclin L2 is a novel member of the cyclin family, recently implicated in the regulation of cell cycle progression and/or transcriptional regulation. The present study was undertaken to investigate the effects of overexpression on tumor cell growth and chemosensitivity in human gastric cells in vitro. Cyclin L2 was transfected into human gastric cancer cell line BCG823 and expressed with a mammalian expression vector pcDNA3.1. The effects and mechanisms of cyclin L2 on cell growth, cell cycling and apoptosis were studied. Compared to control vectors, overexpression of cyclin L2 inhibited the growth of BCG823 cells and enhance their chemosensitivity to fluorouracil, docetaxel and cisplatin. The anti-proliferative effects of cyclin L2 could be due to G0/G1 arrest and apoptosis. Cyclin L2 induced G0/G1 arrest and apoptosis involved upregulation of caspase-3 and down regulation Bcl-2 and survivin. The results indicated that overexpression of cyclin L2 protein may promote efficient growth inhibition and enhance chemosensitivity to chemotherapeutic agents in human gastric cancer cells by inducing G0/G1 cell cycle arrest and apoptosis.

Keywords

References

  1. Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3205-9. https://doi.org/10.1200/JCO.2006.10.4968
  2. Alenzi FQ, Lotfy M, Wyse R (2010). Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev, 11, 271-80.
  3. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. The Lancet, 376, 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
  4. Barton C, Davies D, Balkwill F, et al (2005). Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer, 41, 1474-86. https://doi.org/10.1016/j.ejca.2005.03.022
  5. Duman-Scheel M, Weng L, Xin S, et al (2002). Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature, 417, 299 -304. https://doi.org/10.1038/417299a
  6. Egloff AM, Vella LA, Finn OJ (2006). Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res, 66, 6-9. https://doi.org/10.1158/0008-5472.CAN-05-3389
  7. Graaf K, Hekerman P, Spelte O, et al (2004). Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain phosphorylation by DYRK1A and colocalization with splicine factors. J Biol Chem, 279, 4612-24.
  8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. Ca Cancer J Clin, 6, 69-90.
  9. Lazzarini R, Moretti S, Orecchia S, et al (2008). Enhanced antitumor therapy by inhibion of p21waf1 in human malignant mesothelioma. Clin Cancer Res, 14, 5099-107. https://doi.org/10.1158/1078-0432.CCR-08-0255
  10. Li HL, Wang TS, Li XY, et al (2007). Overexpression of cyclin L2 induces apoptosis and cell-cycle arrest in human lung cancer cells. Chin Med J, 120, 905-9.
  11. Li S, Wang A, Jiang W, et al (2008). Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer, 8, 103-11. https://doi.org/10.1186/1471-2407-8-103
  12. Loyer P, Trembley JH, Grenet JA, et al (2008). Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol Chem, 283, 7721-32. https://doi.org/10.1074/jbc.M708188200
  13. Mori T, Anazawa Y, Matsui K, et al (2002). Cyclin K as a direct transcriptional target of the p53 tumor suppressor. Neoplasia, 4, 268 -74. https://doi.org/10.1038/sj.neo.7900235
  14. Ohtsu A, Shah MA, Van Cutsem E, et al (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol, 29, 3968- 76. https://doi.org/10.1200/JCO.2011.36.2236
  15. Redon R, Hussenet T, Bour G, et al (2002). Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res, 62, 6211-7.
  16. Reedijk J, Lohman PH (1985). Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci, 7, 173-80. https://doi.org/10.1007/BF02307573
  17. Shapiro GI (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol, 24, 1770-83. https://doi.org/10.1200/JCO.2005.03.7689
  18. Swanton C, Marani M, Pardo O, et al (2007). Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell, 11, 498-512. https://doi.org/10.1016/j.ccr.2007.04.011
  19. Tabernero J, Macarulla T, Ramos FJ, et al (2005). Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 16, 1740-8. https://doi.org/10.1093/annonc/mdi355
  20. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: A systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9. https://doi.org/10.1200/JCO.2005.05.0245
  21. Yang L, Li N, Wang C, et al (2004). Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. J Biol Chem, 279, 11639 -48. https://doi.org/10.1074/jbc.M312895200

Cited by

  1. Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review) vol.1, pp.6, 2013, https://doi.org/10.3892/br.2013.158
  2. Cross-talk between the circadian clock and the cell cycle in cancer vol.46, pp.4, 2014, https://doi.org/10.3109/07853890.2014.892296
  3. Knockdown of Med19 Suppresses Proliferation and Enhances Chemo-sensitivity to Cisplatin in Non-small Cell Lung Cancer Cells vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.875
  4. BAD, a Proapoptotic Protein, Escapes ERK/RSK Phosphorylation in Deguelin and siRNA-Treated HeLa Cells vol.11, pp.1, 2016, https://doi.org/10.1371/journal.pone.0145780
  5. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas vol.143, pp.6, 2018, https://doi.org/10.1002/ijc.31418